SIRT7 and familial pancreatic carcinoma: Consequently, the development of SIRT7-based inhibitors may provide a novel strategy for enhancing treatment efficacy in pancreatic cancer, a malignancy characterized by its notorious resistance to conventional therapies and poor prognosis.